Imatinib Koanaa Evropska unija - slovenščina - EMA (European Medicines Agency)

imatinib koanaa

koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastična sredstva - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. bolniki, ki imajo nizko ali zelo nizko tveganje za ponovitev, ne bi smel imeti adjuvant treatment. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. razen v novo diagnozo kronične faze cml, ni kontroliranih preskušanjih, dokazujejo kliničnih koristi ali poveča preživetje pri teh bolezni.

Paxlovid Evropska unija - slovenščina - EMA (European Medicines Agency)

paxlovid

pfizer europe ma eeig - nirmatrelvir, ritonavir - covid-19 virus infection - paxlovid is indicated for the treatment of coronavirus disease 2019 (covid-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe covid 19.

Sevofluran Piramal 250 ml para za inhaliranje, tekočina Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

sevofluran piramal 250 ml para za inhaliranje, tekočina

piramal healthcare uk limited - sevofluran - para za inhaliranje, tekočina - sevofluran 250 ml / 1 ml - sevofluran

Sevofluran Piramal 250 ml para za inhaliranje, tekočina Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

sevofluran piramal 250 ml para za inhaliranje, tekočina

sevofluran - para za inhaliranje, tekočina - sevofluran 250 ml / 1 ml - sevofluran

Heparin Braun 5000 i.e./ml raztopina za injiciranje Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

heparin braun 5000 i.e./ml raztopina za injiciranje

b. braun melsungen ag - heparin - raztopina za injiciranje - heparin 5000 i.e. / 1 ml - heparin

Imprida Evropska unija - slovenščina - EMA (European Medicines Agency)

imprida

novartis europharm ltd - valsartan, amlodipine (as amlodipine besilate) - hipertenzija - sredstva, ki delujejo na sistem renin-angiotenzin - zdravljenje esencialne hipertenzije. imprida je indicirana pri bolnikih, katerih krvni tlak ni ustrezno nadzorovan na amlodipine ali valsartan monotherapy.

Onduarp Evropska unija - slovenščina - EMA (European Medicines Agency)

onduarp

boehringer ingelheim international gmbh - telmisartan - hipertenzija - kardiovaskularni sistem - zdravljenje esencialne hipertenzije pri odraslih:dodaj na therapyonduarp je navedeno pri odraslih, katerih krvni tlak ni ustrezno nadzorovan na amlodipine. zamenjava therapyadult bolnikov, ki prejemajo telmisartan in amlodipine iz ločenih tablet lahko namesto prejeli tablet onduarp, ki vsebuje enake komponente odmerki.

BUPRENORFIN ALKALOID-INT 8 mg podjezične tablete Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

buprenorfin alkaloid-int 8 mg podjezične tablete

alkaloid - int d.o.o. - buprenorfin - podjezična tableta - buprenorfin 8 mg / 1 tableta - buprenorfin

BUPRENORFIN ALKALOID-INT 0,4 mg podjezične tablete Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

buprenorfin alkaloid-int 0,4 mg podjezične tablete

alkaloid - int d.o.o. - buprenorfin - podjezična tableta - buprenorfin 0,4 mg / 1 tableta - buprenorfin

BUPRENORFIN ALKALOID-INT 8 mg podjezične tablete Slovenija - slovenščina - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

buprenorfin alkaloid-int 8 mg podjezične tablete

alkaloid - int d.o.o. - buprenorfin - podjezična tableta - buprenorfin 8 mg / 1 tableta - buprenorfin